Payment overview · 2025
General Payments
$146.90
3 reported records · 3 companies
Healthcare provider profile · identity verified
Sonya Gilmore
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · FORT WALTON BEACH, FL · NPI 1992338636
Verified facts
What the public records show
CMS Open Payments records show Sonya Gilmore received $146.90 in general payments during 2025 across 3 reported records.
GlaxoSmithKline, LLC. accounted for 63.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $92.53 | 63.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $30.09 | 20.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.28 | 16.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $146.90 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $92.53 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $30.09 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $24.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 159 |
| Losartan Potassium | Losartan Potassium | 226 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 185 | 62 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 178 | 48 |
| Metformin Hcl | Metformin Hcl | 177 | 65 |
| Amlodipine Besylate | Amlodipine Besylate | 160 | 56 |
| Omeprazole | Omeprazole | 119 | 43 |
| Gabapentin | Gabapentin | 109 | 45 |
| Glimepiride | Glimepiride | 104 | 34 |
| Tramadol Hcl | Tramadol Hcl | 93 | 29 |
| Furosemide | Furosemide | 92 | 32 |
| Lisinopril | Lisinopril | 92 | 40 |
| Alprazolam | Alprazolam | 85 | 19 |
| Clonidine Hcl | Clonidine Hcl | 84 | 28 |
| Temazepam | Temazepam | 82 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 79 | 27 |
| Montelukast Sodium | Montelukast Sodium | 78 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 28 |
| Meloxicam | Meloxicam | 74 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 32 |
| Carvedilol | Carvedilol | 72 | 28 |
| Ozempic | Semaglutide | 67 | 19 |
| Sertraline Hcl | Sertraline Hcl | 64 | 19 |
| Allopurinol | Allopurinol | 61 | 23 |
| Buspirone Hcl | Buspirone Hcl | 61 | 14 |
| Potassium Chloride | Potassium Chloride | 60 | 17 |
| Trazodone Hcl | Trazodone Hcl | 60 | 22 |
| Eliquis | Apixaban | 59 | 15 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 21 |
| Clonazepam | Clonazepam | 53 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 45 | 17 |
| Trulicity | Dulaglutide | 45 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 16 |
| Ezetimibe | Ezetimibe | 43 | 15 |
| Alendronate Sodium | Alendronate Sodium | 42 | 14 |
| Finasteride | Finasteride | 42 | 13 |
| Ondansetron Odt | Ondansetron | 42 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 38 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 11 |
| Pregabalin | Pregabalin | 38 | 15 |
| Valacyclovir | Valacyclovir Hcl | 36 | suppressed |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 33 | 12 |
| Valsartan | Valsartan | 33 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | 12 |
| Methylprednisolone | Methylprednisolone | 30 | 25 |
| Nystatin | Nystatin | 30 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 29 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 28 | suppressed |
| Fenofibrate | Fenofibrate | 28 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | 12 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Famotidine | Famotidine | 26 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | suppressed |
| Jardiance | Empagliflozin | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Azithromycin | Azithromycin | 19 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | 13 |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 11 |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $146.90 · 3 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, COMIRNATY, MAVYRET, PREVNAR 20 | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error